COVID-19 Seroprevalence Study in French Guiana

Not Applicable

Completed

• Conditions: Severe Acute Respiratory Syndrome; Covid19; Coronavirus Infection; SARS-CoV Infection
• Interventions: Procedure: Blood sample

• Registration Number: NCT04490850
• Lead Sponsor: Institut Pasteur

Brief Summary

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

Detailed Description

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

This study is a interventional study that present minimal risks and constraints.

The results of the study will allow estimation of COVID-19 virus infection, severity and attack rates, as well as inform public health responses and policy decisions in the French Guiana territory.

Study Timeline

• Study Start: 2020-07-15
• Study First Submitted: 2020-07-28
• Study First Submitted QC: 2020-07-28
• Study First Posted: 2020-07-29
• Primary Completion: 2021-09-24
• Study Completion: 2021-09-24
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-14
• Last Update Posted: 2022-02-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3541

Inclusion Criteria

• Person going to a prevention and care center or medical biology analysis laboratory as part of the care, regardless age, regardless of an acute or previous infection with COVID-19;
• State of health compatible with a blood sample as defined in the protocol

Exclusion Criteria

• Inability to consent
• Person under guardianship or curatorship
• Known pathology or a health problem contraindicated with the collect of blood sample.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Participants	Blood sample	Blood sample

Primary Outcome Measures

Name	Time	Method
Measure of the COVID-19 immunity of the population	1 year	The COVID-19 immunity of the population will be assessed by evaluating the anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies

Secondary Outcome Measures

Name	Time	Method
Evaluation of the level of asymptomatic and pauci-symptomatic infections	1 year	The proportion of asymptomatic and pauci-symptomatic infections will be measured in the population

Trial Locations

Locations (5)

Laboratoires Eurofins Guyane; 🇬🇫 Cayenne, French Guiana

Centre Hospitalier Andrée Rosemon; 🇬🇫 Cayenne, French Guiana

Laboratoire de biologie médicale de Kourou; 🇬🇫 Kourou, French Guiana

Laboratoire de biologie méicale, Institut Pasteur de la Guyane; 🇬🇫 Cayenne, French Guiana

Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni; 🇬🇫 Saint-Laurent du Maroni, French Guiana